Acumen Pharmaceuticals (ABOS) Interest Expenses (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Interest Expenses data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 4.5% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 42.52% YoY), and the FY2025 full-year result was $85.5 million, up 51.53% from the prior year.
• Interest Expenses slipped to $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $39.8 million in Q3 2022 to a low of -$114000.0 in Q4 2022.
• A 5-year average of $3.8 million and a median of $1.0 million in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 173021.74% in 2022, while the deepest fall reached 395.65% in 2022.
• Tracing ABOS's Interest Expenses over 5 years: stood at -$114000.0 in 2022, then surged by 248.25% to $169000.0 in 2023, then tumbled by 134.32% to -$58000.0 in 2024, then jumped by 1974.14% to $1.1 million in 2025, then slipped by 1.66% to $1.1 million in 2026.
• Business Quant data shows ABOS's Interest Expenses at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.